VKTX
Viking TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Positive clinical readouts or a strategic partnership meaningfully de‑risk programs and push valuation toward premium biotech multiples (~$58/share).
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +2.4.
What can break
Trial failures, persistent cash burn, or dilutive financing compress valuation toward the low‑twenties (~$23/share).
Momentum
25
Value
41
Sentiment
84
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $38.55 · Bull $57.83 · Bear $23.13
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2025-12-08 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $93.59
Why
Momentum25 · Δ7d +11.7
Value41 · Δ7d +0.1
Sentiment84 · Δ7d +2.4
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
25
34% active weight
Current posture
7d trendImproving
Δ7d
+11.7
Δ21d
+2.9
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
84
33% active weight
Current posture
7d trendImproving
Δ7d
+2.4
Δ21d
+11.0
Why this grade
Composite grade C. Momentum 25.4 / Value 41.1 / Sentiment 83.7
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$3.63B
Beta
0.76
Shares Out
113.04M
P/E (TTM) · Derived
-10.1
P/S (TTM)
-
P/FCF (TTM) · Derived
-16.01
Rev YoY
-
EPS YoY
-259.5%
Gross Margin
-
Op Margin
-
Net Debt
-$902.61M
Current Ratio
28.34
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology